Currently, there is a paucity of approved disease‐modifying drugs specifically for improving OA outcomes.[7a] However, JAKi, such as tofacitinib, is clinically used to treat rheumatoid arthritis (RA) by effectively reducing synovial inflammation and preventing RA‐induced cartilage erosion.[20] In human degenerated cartilage, the number of p‐JAK1 and p‐JAK3 positive cells was significantly increased compared to relatively healthy cartilage (Figure S10, Supporting Information). This evidence concerns the gene JAK3 and rheumatoid arthritis.